12/19
09:03 am
sabs
Rating for SABS
Low
Report
Rating for SABS
12/19
09:03 am
sabs
Rating for SABS
Low
Report
Rating for SABS
12/19
07:02 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/19
07:02 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/19
06:31 am
sabs
SAB Biotherapeutics initiated with a Buy at Guggenheim
Low
Report
SAB Biotherapeutics initiated with a Buy at Guggenheim
12/19
06:31 am
sabs
SAB Biotherapeutics initiated with a Buy at Guggenheim
Low
Report
SAB Biotherapeutics initiated with a Buy at Guggenheim
12/18
08:05 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
12/18
07:35 am
sabs
Rating for SABS
Medium
Report
Rating for SABS
11/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/17
07:10 am
sabs
Rating for SABS
Medium
Report
Rating for SABS